Monday, August 31, 2026

Beyond Meat Stock Plummets 34% In 21 Sessions: What's Next?

ViaNews Editorial Team

October 24, 2023

Beyond Meat Stock Plummets 34% In 21 Sessions: What's Next?

(VIANEWS) - Shares of Beyond Meat (NASDAQ: BYND) experienced an astonishing 34.68% decline over 21 sessions, from EUR9.4 on 2023-09-25 to EUR6.14 at 18:41 EST on Tuesday afternoon - following five straight losses and as the NASDAQ index continued its upward trend from prior sessions - falling 34.68% over that timeframe and closing at EUR6.29 which is 72.5% below its 52-week high of EUR22.87.

About Beyond Meat

Beyond Meat is an industry-leading developer and manufacturer of plant-based meat alternatives available through various retail and foodservice channels worldwide. Established in 2009, Beyond Meat provides plant-based alternatives across beef, pork and poultry platforms - which it was rebranded from Savage River Inc in September 2018 with the focus of providing sustainable, healthy and tasty alternatives.

Yearly Analysis

Based on this data, Beyond Meat's stock is trading below its 52-week low, suggesting it may be undervalued. Investors should however remain wary as sales growth is forecasted to be negative this year - an indication of potential financial hardship - while EBITDA of -38.11 indicates it may not currently be profitable. Negative sales growth and EBITDA should both serve as red flags to potential investors. Such indicators could signal increased competition, shifting consumer tastes or supply chain disruptions; and EBITDA suggests the company is not currently generating enough revenue to cover operating expenses which may signal financial distress. Overall, investors should carefully assess Beyond Meat's financial performance and fundamentals prior to making any investment decisions. If possible, investors may wait until Beyond Meat shows sustained improvements in its finances before considering investing.

Technical Analysis

Beyond Meat is currently experiencing a marked decrease in value with stock prices trading far below both its 50-day and 200-day moving averages, as evidenced by trading volume dipping 9.44% below its average of 19,607,700 shares traded per day. Additionally, the company's volatility has seen a decrease over the last week, month and quarter; with its current intraday variation average being negative 7.13% for week one and month one and positive 3.08% for month three and quarter three, respectively - possibly signifying an shift in market sentiment towards their stock. Additionally, Beyond Meat's stock has been designated by the stochastic oscillator as being overbought, as indicated by an oscillator reading of 80 or higher on its stochastic oscillator indicator - suggesting it may have become overvalued and require correcting at some point in the near future. Beyond Meat's current stock prices and technical indicators suggest that its stock could soon experience a downturn, so investors should exercise extreme caution and closely track Beyond Meat in the coming weeks and months in order to make informed investments decisions.

Quarter Analysis

Beyond Meat (BYND) has experienced mixed performance when it comes to sales growth and revenue expansion. Although current and next quarter sales increases are positive at 6.6% and 4.2%, respectively compared with historical rates; this indicates that momentum may be shifting away from growth for BYND. Revenue growth at the company has fallen by 30.5% year-on-year over quarter one, totaling 356.82M for twelve trailing months. This can be attributed to the impact of COVID-19 pandemic on its business operations and supply chain. Beyond Meat has seen revenue decline year over year; yet their projected quarterly and yearly growth estimates still look promising: 46.9% and 27.6%, respectively. This impressive expansion can be attributed to Beyond Meat's innovative product offerings and growing distribution channels. Overall, investors should approach Beyond Meat with caution given its moderate sales growth and decreasing revenue growth. Positive estimates for this quarter and next may point toward future potential for expansion and profitability; it is recommended that further research be conducted before making an investment decision.

Equity Analysis

Beyond Meat is currently experiencing negative earnings with an EPS of EUR-4.4, meaning they do not generate sufficient profits to cover operating expenses and instead relying on other forms of income or capital to remain operational. Investors should take note of this negative trend and consider carefully whether Beyond Meat can turn its financial performance around in the near future. To determine this possibility further they could research Beyond Meat's growth potential, competitive landscape, industry trends or growth potential to assess whether there may be opportunity for future profitability and positive earnings growth.

More news about Beyond Meat (BYND).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com